ImmunityBio (IBRX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $8.0B, trading at $7.63 on the NASDAQ. This SniperIQ fundamentals page covers ImmunityBio's valuation, profitability (net margin -606.2%), revenue (
13M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap$8.0B
Net Margin-606.2%
Revenue (FY25)
13M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is ImmunityBio's market cap?
ImmunityBio (IBRX) has a market capitalization of approximately $8.0B, trading at $7.63 on the NASDAQ. Market cap moves with the live share price.
How profitable is ImmunityBio?
ImmunityBio runs a net profit margin of -606.2%, a gross margin of 93.8%, and an operating margin of -185.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does ImmunityBio generate?
ImmunityBio reported revenue of
13M for fiscal year 2025, with net income of -
51M and earnings per share (EPS) of -0.38. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does ImmunityBio pay a dividend?
ImmunityBio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ImmunityBio financially healthy?
ImmunityBio carries a debt-to-equity ratio of -1.29x and a current ratio of 6.67x, with a market beta of 0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ImmunityBio a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ImmunityBio (IBRX) the key facts are: market cap $8.0B, revenue
13M, 52-week range 1.95-12.43. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ImmunityBio's full fundamentals live
Get ImmunityBio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.